Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry).
Ielasi A, Cortese B, Varricchio A, Tespili M, Sesana M, Pisano F, Loi B, Granata F, Moscarella E, Silva Orrego P, La Vecchia L, Steffenino G; RAI registry investigators. Ielasi A, et al. Among authors: silva orrego p. EuroIntervention. 2015 Jun;11(2):157-62. doi: 10.4244/EIJY14M10_11. EuroIntervention. 2015. PMID: 25354760 Free article. Clinical Trial.
Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Cortese B, et al. Among authors: silva orrego p. Am J Cardiol. 2015 Sep 1;116(5):705-10. doi: 10.1016/j.amjcard.2015.05.049. Epub 2015 Jun 3. Am J Cardiol. 2015. PMID: 26100584 Clinical Trial.
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
Moscarella E, Tanaka A, Ielasi A, Cortese B, Coscarelli S, De Angelis MC, Piraino D, Latib A, Grigis G, Bianchi R, Buccheri D, Calabrò P, Tespili M, Silva Orrego P, Colombo A, Varricchio A. Moscarella E, et al. Among authors: silva orrego p. Catheter Cardiovasc Interv. 2018 Oct 1;92(4):668-677. doi: 10.1002/ccd.27473. Epub 2018 Jan 22. Catheter Cardiovasc Interv. 2018. PMID: 29356269
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry.
Moscarella E, Ielasi A, Varricchio A, Cortese B, Loi B, Tarantini G, Pisano F, Durante A, Pasquetto G, Colombo A, Tumminello G, Moretti L, Calabrò P, Mazzarotto P, Tespili M, Silva Orrego P, Corrado D, Steffenino G; RAI Investigators. Moscarella E, et al. Among authors: silva orrego p. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):404-410. doi: 10.1002/ccd.27845. Epub 2018 Oct 22. Catheter Cardiovasc Interv. 2019. PMID: 30346080
Comparison of risk of acute kidney injury after primary percutaneous coronary interventions with the transradial approach versus the transfemoral approach (from the PRIPITENA urban registry).
Cortese B, Sciahbasi A, Sebik R, Rigattieri S, Alonzo A, Silva-Orrego P, Belloni F, Seregni RG, Giovannelli F, Tespili M, Ricci R, Berni A. Cortese B, et al. Among authors: silva orrego p. Am J Cardiol. 2014 Sep 15;114(6):820-5. doi: 10.1016/j.amjcard.2014.06.010. Epub 2014 Jul 1. Am J Cardiol. 2014. PMID: 25073568
22 results